A detailed history of Vanguard Group Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,765,325 shares of XERS stock, worth $26.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,765,325
Previous 7,656,890 1.42%
Holding current value
$26.2 Million
Previous $17.2 Million 28.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.06 - $2.96 $223,376 - $320,967
108,435 Added 1.42%
7,765,325 $22.1 Million
Q2 2024

Aug 13, 2024

BUY
$1.7 - $2.45 $86,101 - $124,087
50,648 Added 0.67%
7,656,890 $17.2 Million
Q1 2024

May 10, 2024

BUY
$2.04 - $3.22 $1.06 Million - $1.67 Million
519,897 Added 7.34%
7,606,242 $16.8 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $88,466 - $142,027
60,181 Added 0.86%
7,086,345 $16.7 Million
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $134,217 - $200,579
74,565 Added 1.07%
7,026,164 $13.1 Million
Q2 2023

Aug 14, 2023

BUY
$1.82 - $2.98 $201,137 - $329,334
110,515 Added 1.62%
6,951,599 $18.2 Million
Q1 2023

May 15, 2023

BUY
$1.03 - $1.63 $250,421 - $396,298
243,128 Added 3.68%
6,841,084 $11.2 Million
Q4 2022

Feb 10, 2023

BUY
$1.14 - $1.65 $100,574 - $145,567
88,223 Added 1.36%
6,597,956 $8.78 Million
Q3 2022

Nov 14, 2022

BUY
$1.37 - $1.93 $296,265 - $417,366
216,252 Added 3.44%
6,509,733 $10.2 Million
Q2 2022

Aug 12, 2022

BUY
$1.48 - $2.64 $1.61 Million - $2.87 Million
1,085,295 Added 20.84%
6,293,481 $9.69 Million
Q1 2022

May 13, 2022

BUY
$2.0 - $2.87 $185,126 - $265,655
92,563 Added 1.81%
5,208,186 $13.3 Million
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $9.21 Million - $15 Million
5,115,623 New
5,115,623 $15 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $460M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.